APLS
NASDAQ · Biotechnology
Apellis Pharmaceuticals Inc
$17.72
+0.49 (+2.84%)
Performance
1D
—
1W
—
1M
—
3M
-29.03%
6M
-21.77%
1Y
-25.51%
YTD
-31.48%
Open$17.44
Previous Close$17.23
Day High$17.96
Day Low$17.39
52W High$30.48
52W Low$16.10
Volume—
Avg Volume2.22M
Market Cap2.58B
P/E Ratio115.05
EPS$0.12
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$23.47
Below
SMA 200
$22.25
Below
RSI (14)
47.9
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
29 analysts
Price Target
+27.2% upside
Current
$17.72
$17.72
Target
$22.54
$22.54
$12.93
$22.54 avg
$29.12
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.02B | 3.03B | 2.81B |
| Net Income | 22.73M | 93.04M | 81.85M |
| Profit Margin | 2.2% | 3.1% | 2.9% |
| EBITDA | 57.73M | 115.17M | 115.66M |
| Free Cash Flow | — | 42.87M | 48.47M |
| Rev Growth | +137.0% | +21.3% | +20.6% |
| Debt/Equity | 1.23 | 0.57 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |